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Abstract
Introduction: Authors of several studies have studied biomarkers and computed tomography (CT) findings in the
acute phase after severe traumatic brain injury (TBI). However, the correlation between structural damage as
assessed by neuroimaging and biomarkers has not been elucidated. The aim of this study was to investigate the
relationships among neuronal (Ubiquitin carboxy-terminal hydrolase L1 [UCH-L1]) and glial (glial fibrillary acidic
protein [GFAP]) biomarker levels in serum, neuroradiological findings and outcomes after severe TBI.
Methods: The study recruited patients from four neurotrauma centers. Serum samples for UCH-L1 and GFAP were
obtained at the time of hospital admission and every 6 hours thereafter. CT scans of the brain were obtained
within 24hrs of injury. Outcome was assessed by Glasgow Outcome Scale (GOS) at discharge and at 6 months.
Results: 81 severe TBI patients and 167 controls were enrolled. The mean serum levels of UCH-L1 and GFAP were
higher (p < 0.001) in TBI patients compared to controls. UCH-L1 and GFAP serum levels correlated significantly with
Glasgow Coma Scale (GCS) and CT findings. GFAP levels were higher in patients with mass lesions than in those with
diffuse injury (2.95 ± 0.48 ng/ml versus 0.74 ± 0.11 ng/ml) while UCH-L1 levels were higher in patients with diffuse
injury (1.55 ± 0.18 ng/ml versus 1.21 ± 0.15 ng/ml, p = 0.0031 and 0.0103, respectively). A multivariate logistic regression
showed that UCH-L1 was the only independent predictor of death at discharge [adjusted odds ratios 2.95; 95%
confidence interval, 1.46-5.97], but both UCH-L1 and GFAP levels strongly predicted death 6 months post-injury.
Conclusions: Relationships between structural changes detected by neuroimaging and biomarkers indicate each
biomarker may reflect a different injury pathway. These results suggest that protein biomarkers could provide
better characterization of subjects at risk for specific types of cellular damage than that obtained with
neuroimaging alone, as well as provide valuable information about injury severity and outcome after severe TBI.
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Introduction
Accurate determination of the initial severity of primary
brain damage after severe head injury is crucial for
establishing neurologic prognosis and to balance the
risks and benefits of treatment [1]. Outcome prediction
remains difficult because neurologic assessment is often
influenced by the use of sedatives, analgesics, or muscle
relaxants. Assessment of structural damage by neuroi-
maging is not influenced by these confounders. Marshall
and colleagues [2] proposed a descriptive system of
computed tomography (CT) classification, which focuses
on the presence or absence of a mass lesion and differ-
entiates diffuse injuries by signs of increased intracranial
pressure. However, the Marshall classification has lim-
itations. This classification system might mask patients
who have diffuse axonal injury (DAI) or signs of raised
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intracranial pressure (ICP) in addition to a mass lesion,
and does not fully use the prognostic information con-
tained in the individual CT characteristics scored [3].
Furthermore, CT has not reliably predicted outcome
and can only capture momentary snapshots of the dyna-
mically evolving process of TBI, and important lesions
that occur at the microscopic level cannot be visualized.
Biologic markers that reliably reflect either the extent
of brain damage and microscopic pathological events
and are easy to measure (i.e., in peripheral blood) have
long been sought [4]. Biomarkers might mirror evolving
processes in the brain that occur at the microscopic
level as well as track pathophysiological mechanisms
that underlie damage following severe traumatic brain
injury (TBI).
Ubiquitin C-terminal Hydrolase-L1 protein (UCH-L1),
highly enriched and specifically expressed in neurons, is
involved in either the addition or removal of ubiquitin
from abnormal proteins including misfolded proteins,
and proteins damaged by oxidation or denatured by
other means, that are destined for proteasomal degrada-
tion [5]. A recent study reported that levels of UCH-L1
in cerebrospinal fluid (CSF) were significantly increased
in severe TBI and found a significant association with
severity measures [6].
Glial fibrillary acidic protein (GFAP) is a monomeric
intermediate filament protein of astrocytes and is con-
sidered specific for central nervous system (CNS) dis-
ease. Recently, other reports have confirmed that serum
GFAP is a specific marker of brain damage after head
trauma [7,8].
The objectives of our study were: to evaluate early
values and trends of biomarker levels and associations
with neuroradiological findings assessed by the Marshall
score; to determine the prognostic value of serum con-
centrations of UCH-L1 and GFAP for clinical outcome
at discharge and at six months; and to assess if the asso-
ciation of different biomarkers and clinical indices of
severity could be a more a powerful predictor of out-
come after severe TBI than clinical indices alone.
Materials and methods
Study sites, design, and population
Approval of this study was obtained from the local
ethics committee of all the sites involved and from the
Western Institutional Review Board and Human
Research Protection Office. Eighty-one adult patients
presenting to the University of Pécs (n = 30), University
of Szeged (n = 21), and University of California Davis
(n = 20), and from the University of Maryland Shock
Trauma Center (n = 10) with severe head injury were
included in this prospective multicenter study. Sixty-one
patients presented with isolated head injury. Twenty
severe TBI patients had minor concomitant injury of the
thorax and ⁄or abdomen and/or extremities. Multiple
trauma were excluded (see exclusion criteria, below).
Written informed consent was obtained from a next of
kin because all eligible patients were in coma within 24
hours from the admission. Exclusion criteria were no
informed consent, patients younger than 18 years of age,
female patients that were or may have been pregnant,
known history of neurological disease, and Injury Sever-
ity Score (ISS) greater than 15. Inclusion criteria were a
Glasgow Coma Score (GCS) score of eight or less on
presentation. Treatment of patients, according to inter-
national guidelines, was targeted at a normal ICP and
maintaining cerebral perfusion pressure [9]. Initial CT
scans obtained on admission were analyzed according to
the classification of Marshall and colleagues [2]. CT
scans were interpreted by a qualified neuroradiologist at
a central location. For the purpose of our analysis, Mar-
shall was further classified into two groups using dichot-
omized categories (diffuse injury versus focal mass
lesion), as previously described [10]. Outcome was
assessed as in-hospital mortality and at six months
using the Glasgow Outcome Scale (GOS) [11].
In addition, 167 healthy blood donors were enrolled,
during a one-year period, to establish normal serum
UCH-L1 and GFAP levels.
Analysis of UCH-L1 and GFAP
Venous blood samples were taken at hospital admission
(median seven hours) and every six hours thereafter. For
the purpose of the analysis and to handle potential miss-
ing samples, time after injury for each sample was calcu-
lated and the samples were separated into 12 or 24-hour
time period. Approximately 5 mL of serum was col-
lected from each subject at each sample point. Samples
were centrifuged for 10 minutes at 4,000 rpm and
immediately frozen and stored at -70°C until the time of
analysis. Samples were measured using a standard UCH-
L1 sandwich ELISA protocol as described below. Reac-
tion wells were coated with capture antibody (500 ng/
well purified anti-rabbit UCHL1, made in-house) in 0.1
M sodium bicarbonate, pH 9 and incubated overnight at
4°C. Plates were then emptied out and 300 μl/well
blocking buffer (Startingblock T20-TBS) was added and
incubated for 30 minutes at ambient temperature with
gentle shaking. This was followed by addition of antigen
standard (UCHL1 standard curve: 0.05 to 50 ng/well)
unknown samples (3 to 10 uL CSF) or assay internal
control samples. The plate was incubated for two hours
at room temperature then washed using an automatic
plate washer (each well rinsed with 5 × 300 μl with
wash buffer (TBST)). Detection antibody (anti-rabbit
UCH-L1-HRP conjugation, made in-house at 50 μg/mL)
in blocking buffer was then added to wells at 100 μl/
well and the plates were further incubated for 1.5 hours
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at room temperature. After additional automatic wash-
ing, biotinyl-tyramide solution (Elast ELISA Amplifica-
tion Kit, PerkinElmer, Inc., Waltham, MA, USA) was
added and the plate was incubated for 15 minutes at
room temperature followed by automatic washing. Addi-
tion of streptavidin-HRP (1:500, 100 ul/well) in PBS
with 0.02% Tween 20 and 1% BSA for 30 minutes incu-
bation at room temperature was followed by automatic
washing. Finally, the wells were developed with substrate
solution: Ultra-TMB ELISA 100 ul/well (Pierce# 34028)
with incubation for 5 to 30 minutes and read at 652 nm
with a 96- well spectrophotometer (Spectramax 190,
Molecular Device, Sunnyvale, CA, USA). GFAP protein
was analyzed using a commercially available (Biovendor
Laboratory Medicine Inc., catalog n° rd192072200, Brno,
Czech Republic) polyclonal two-side immunolumino-
metric assay according to the manufacturer’s instruc-
tions. A standard curve was constructed by plotting
absorbance values versus GFAP concentrations of
calibrators.
Statistical methods
The Mann-Whitney test was used to test differences
between groups in glial and neural proteins, separately
for significance in case of two groups and the Kruskal-
Wallis test was used in case of three or more groups.
Spearman correlations were used to test correlations
between clinical variables and biomarkers. Univariate
logistic regression was used to evaluate the prognostic
ability of the clinical and biochemical variables,
separately, to predict the probability of being deceased
(GOS = 1) at discharge and six months after severe TBI.
c-statistic (the area under an receiver operating charac-
teristic (ROC) curves) provides an overall measure of
classification accuracy (representing the overall propor-
tion of individuals correctly classified), with the value of
1.0 representing perfect accuracy. A ROC curve was cre-
ated to explore the ability of the biomarker to construct
reasonable cutoff values for these variables to predict
survival. The optimal cutoff value was chosen as the
best operating point. Crude odds ratios (OR) with 95%
confidence intervals (CIs) are presented. The Marshall
classification was treated as an ordered variable, and the
GCS was treated as continuous variables. Multivariate
logistic regression with forward stepwise selection pro-
cedures was used to identify variables that contributed
independently to the risk of being deceased at discharge
or six months after severe TBI. Adjusted ORs with 95%
CIs are presented. All tests were two-tailed. A P value
less than 0.05 was considered significant. The software
package SAS 9.2 (SAS Institute, Inc., Cary, NC, USA)
was used for the statistical analyses.
Results
The clinical and demographic characteristics of the 81
patients included in this study are summarized in Table
1. Mean UCH-L1 serum concentrations in the first 24
hours in the TBI patients were 1.36 ± 0.11 ng/ml and
0.12 ± 0.02 ng/ml in controls (P < 0.0001), and for
GFAP it was 2.01 ± 0.29 ng/ml versus 0.07 ± 0.03 ng/ml
(P < 0.0001). UCH-L1 concentrations were strongly cor-
related with GFAP (R = 0.53, P < 0.001).
Furthermore, the mean serum UCH-L1 and GFAP
concentrations were higher in patients who died com-
pared with patients who were alive at six months post-
injury (UCH-L1 1.6 ± 0.22 ng/ml versus 0.65 ± 0.07 ng/
ml, P = 0.01, and GFAP 3.3 ± 0.57 ng/ml versus 0.36 ±
0.14 ng/ml P < 0.001, Mann-Whitney U test).
Serum UCH-L1 and GFAP levels obtained within 12
hours post- injury were higher in subjects with a GCS 3
to 5 (n = 47) than in those with a GCS 6 to 8 (n = 34)
as recorded on the admission (P = 0.01 and P = 0.001,
respectively, test based on the Mann-Whitney statistic).
Thirty-six patients (44%) presented with diffuse injury
(Marshall I to IV) and 45 patients (56%) with focal mass
lesions (Marshall V to VI) on initial CT scan (Table 1).
The average values of UCH-L1 in the first 24 hours
post-injury were 1.55 ± 0.18 ng/ml in diffuse injury and
significantly lower (1.21 ± 0.15 ng/ml) in focal mass
lesion (P = 0.01). In contrast, GFAP levels were signifi-
cantly higher in patients with focal mass lesion (Mar-
shall V to VI) compared to patients with diffuse injury
(Marshall I to IV) (2.95 ± 0.48 ng/ml versus 0.74 ± 0.11
ng/ml, P = 0.003, test based on Mann Whitney U).
Marshall Classification was also categorized into three
groups. Diffuse injury I to II, diffuse injury III to IV, and
focal mass lesion. The average levels of UCH-L1 in the
first 24 hours post-injury were 1.27 ± 0.23 ng/ml, 1.93 ±
0.3 ng/ml and 1.22 ± 0.15 ng/ml. Average GFAP levels
were 0.56 ± 0.12 ng/ml, 1 ± 0.2 ng/ml and 2.95 ± 0.48
ng/ml (P = 0.0006 and P = 0.016, respectively, Kruskal-
Wallis test) (Figures 1a and 1b). Two main different pat-
terns were recognized in diffuse injury versus focal mass
lesions for both UCH-L1 and GFAP levels in the first 24
hours post-injury (Figures 1c and 1d). GFAP levels were
higher in patients with mass lesion than in patients with
diffuse injury (P = 0.006), whereas UCH-L1 levels were
significantly higher in patients with diffuse injury than
in patients with mass lesion (P = 0.01, Mann Whitney U
test). An example of injury patterns in individual
patients with diffuse injury or a mass lesion is provided
in Figure 2.
Levels of UCH-L1, but not levels of GFAP were
weakly correlated with age in patients with severe TBI
(correlation coefficient = -0.22, P = 0.04).
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At six month follow up, the mortality rate was 45.44%.
Table 2 shows the crude ORs with the 95% CIs of
serum biomarkers and GCS, CT characteristics classified
by Marshall score, age, and gender for the prediction of
death (GOS 1): either in hospital mortality or at six
months. The c-statistic (representing the overall propor-
tion of individuals correctly classified) was higher for
the biomarkers compared with the other variables for
survival prediction at discharge. Figure 3 shows that
patients with high biomarker levels in the first 24 hours
had an increased mortality at six month after injury.
For the outcome of in-hospital mortality, multivariate
logistic regression analysis revealed that from all vari-
ables used in the selection procedure UCH-L1 was the
only independent predictor (P < 0.05). This result may
not be surprising because we found highly significant
correlations between UCH-L1 and GFAP. UCH-L1 also
significantly associated with GCS and Marshall score. In
addition, spline function analysis shows the risk of in-
hospital mortality correlated to UCH-L1 serum levels
(Figure 4).
As we were specifically interested in discriminating in-
hospital mortality optimal cutoff values were calculated
by using the criteria of equal-cost-of-misclassification.
The specificity in predicting in-hospital mortality of
both biomarkers was very high although the sensitivity
was low (Table 3).
For six months mortality, a multivariate logistic
regression analysis revealed that age was the most signif-
icant independent predictor (OR 1.12, 95% CI 1.05 to
1.19, P = 0.001) followed by UCH-L1 (OR 8.21, 95% CI
1.73 to 38.92, P = 0.01) and the GCS (OR 0.58, 95% CI
0.35 to 0.95, P = 0.04, c = 0.94). GFAP did not have an
additional contribution when UCH-L1 was already
entered in the model. For this outcome, GFAP was
found have a similar predictive value to UCH-L1 (c =
0.93), where age was the most significant independent
predictor (OR 1.1, 95% CI 1.08 to 1.18, P = 0.002)





Age, y, mean (SD) 47.89 ± 20.35 36.91 ± 14.06
Gender, n (%) Female 16 (19.75) 72 (43.1)
Male 65 (80.25) 95 (56.9)
Race, n (%) Asian 3 (3.7) 6 (3.6)
Black or African American 7 (8.64) 26 (15.6)
Caucasian 70 (86.42) 134 (80.2)
Other 1 (1.23) 1 (0.6)
Ethnic, n (%) Hispanic or Latino 2 (2.47) 13 (7.8)
Not Hispanic or Latino 79 (97.53) 146 (87.4)
Other - 8 (4.8)
Injury Mechanism, n (%) Motor Vehicle Accident 30 (37.04) -
Motor Cycle Accident 3 (3.7) -
Gun Shot Wound 2 (2.47) -
Fall 32 (39.51) -
Assault 4 (4.94) -
Other 10 (12.35) -
GCS, median (range)* 5 (3-8) 15
Marshall Score, n (%) Diffuse Injury I 1 (1.23) -
Diffuse Injury II 20 (24.69) -
Diffuse Injury III 9 (11.11) -
Diffuse Injury IV 6 (7.41) -
Evacuated Focal Mass Lesion V 4 (4.94) -
Focal Mass Lesion VI 41 (50.62) -
Outcome -
In hospital, n (%) Deceased (GOS 1) 28 (34.57) -
Alive (GOS 2-5) 53 (65.43) -
6 months, n (%) Deceased (GOS 1) 35 (45.44) -
Alive (GOS 2-5) 42 (54.56) -
Missing 4 -
* At the time of admission
GCS: Glasgow Coma Scale score; GOS: Glasgow Outcome Scale; TBI: traumatic brain injury.
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followed by GFAP (OR 4.88, 95% CI 1.37 to 17.36, P =
0.01) but GCS dropped out of model (OR 0.64, 95% CI
0.38 to 1.09, P = 0.1).
Finally, Figure 5 shows the increased mortality risk in
patients with Marshall Score III to IV, consistent with
the observation that UCH-L1 (which is elevated more
than GFAP in these patients) is an important predictor
of mortality.
Discussion
This prospective study in 81 patients with severe TBI
demonstrates that assessment of injury severity and
prediction of outcome after severe TBI may be
improved with the determination of serum levels of
brain specific proteins (UCH-L1 and GFAP) during the
acute phase of injury.
The classification of initial CT findings developed by
Marshall and colleagues [2] is widely accepted as a clas-
sification that allows an evaluation of injury severity in
the acute setting. In agreement with previous studies,
we found a correlation between the initial serum UCH-
L1 and GFAP level and the intracranial diagnosis
assessed by Marshall score [6,8].
Importantly, this is the first study to report signifi-
cantly different pathways for UCH-L1 and GFAP to dif-
ferent type of brain injured patients as characterized by
neuroimaging (diffuse injury versus focal mass lesion)
(Figures 1c and 1d), including the finding that the two
biomarkers had different temporal profile in the same
type of injury.
GFAP serum concentrations were higher in patients
with with focal mass lesion (Marshall V to VI) than
Figure 1 Serum levels of ubiquitin C-terminal hydrolase-L1 protein (UCH-L1) and glial fibrillary acidic protein (GFAP) in patients with
diffuse injury or focal mass lesion. (a and b) Box plots of biomarker boxes enclose 25th to 75th percentiles; vertical whiskers extend to 10th
and 90th percentiles. Median (50th percentile) is marked by the line inside the box; mean is marked by the diamond; outliers are plotted with
circles. (a) Serum levels of UCH-L1 versus Marshall Score (Diffuse Injury vs Focal Mass Lesion) (Kruskal-Wallis Test, P = 0.0006). (b) Serum levels
GFAP versus Marshall Score (Diffuse Injury vs Focal Mass Lesion) (Kruskal-Wallis Test, P = 0.0163). (c and d) Scatterplot with average smoothing
superimposed on a graph of (c) UCH-L1 and in (d) GFAP levels versus time. The figure was generated using the LOWESS (LOcally WEighted
Scatterplot Smoother) technique to draw a smooth line representing the average value of the variable on the y-axis as a function of the variable
on the x-axis.
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in patients with diffuse injury (Marshall I to IV). In
focal mass lesion, GFAP levels tended to remain
abnormally elevated over time. In diffuse injury,
GFAP levels were relatively low tended to remain low
over the monitoring period (Figure 1d). Conversely,
in patients with mass lesion UCH-L1 levels were
initially higher than in patients with diffuse injury
and tended to normalize over the monitoring period.
In diffuse injury, UCH-L1 levels were initially high
but tended to increase over time or remain abnor-
mally elevated (Figure 1c).
Different patterns of biomarker release imply that dif-
ferent patterns of structural damage involve different
pathophysiological mechanisms and may require differ-
ent therapeutic approaches. Biomarkers analyzed in our
study were both brain-specific proteins, UCH-L1 is a
neuronal protein while GFAP is a glial protein. Mass
lesions seem to result in more damage to glia (physical
support for neurons), whereas diffuse injury shows more
neuronal injury (functional cells in the brain). It is, in
fact, widely accepted that the neurons are highly sensi-
tive to increased ICP or decreased cerebral perfusion
Figure 2 Ubiquitin C-terminal hydrolase-L1 protein (UCH-L1) and glial fibrillary acidic protein (GFAP) dynamics in human serum after
acute injury. (a and b) Computed tomography scans demonstrating focal and diffuse brain injury in individual patients. (c and d) UCH-L1
(green circles) and GFAP (blue triangles) serum concentrations measured every six hours in corresponding individual patients. Time (x axis)
reflects interval after injury.
Mondello et al. Critical Care 2011, 15:R156
http://ccforum.com/content/15/3/R156
Page 6 of 10
pressure inflicted by both primary trauma and secondary
insults [12-15]. The assessment of the pathobiological
significance of different biomarker pathways and their
clinical relevance in patients with TBI has to be
addressed in future animal and human studies.
Patients in this study showed imaging changes consis-
tent with morphopathological patterns of diffuse and
focal neuronal injury identified following human and
experimental TBI [12,13,16]. Changes in biomarker
levels can provide real-time complementary information
on pathophysiological events that occur in living brain
following a brain injury. Moreover, as brain damage is a
common finding in cases of mild and moderate head
trauma with a broad spectrum of outcomes ranging
from mild post-concussive syndrome [17,18] to moder-
ate and severe disability [19], a better understanding of
specific profiles of cellular damage could be critical aid-
ing in clinical decision making and lead to more effec-
tively targeted therapy.
Interestingly, we found greater increases in levels and
frequency of secondary elevations or sustained high
levels within the first 24 hours of both GFAP and UCH-
L1 in the focal mass lesion group than diffuse injury
(tracked by both biomarkers), suggesting biomarker
levels can be associated with adverse physiological
events following TBI. Although, the presence of second-
ary increases in biomarker levels has been often related
to secondary insults (hypoxia, hypotension, hyperther-
mia) [20], in this group an alternative hypothesis is that
Table 2 Crude OR of clinical and biochemical variables
for death (GOS 1) in hospital and six months after severe
traumatic brain injury using univariate logistic regression
In Hospital Mortality 6 months Mortality
Variable OR (95%CI) C OR (95%CI) C
UCH-L1 2.74 (1.54-4.90)* 0.74 2.29 (1.07-4.90)† 0.62
GFAP 1.41 (1.08-1.84)† 0.76 3.30 (1.21-8.50)† 0.75
Age 1.02 (0.99-1.05) 0.60 1.07 (1.03-2.11)* 0.78
GCS 0.64 (0.45-0.91)† 0.69 0.59 (0.41-0.85)† 0.72
Gender
Female Reference Reference
Male 1.01 (0.80-1.29) 0.60 0.69 (0.19-2.58) 0.53
Marshall Score
I-II Reference Reference
III-IV 9.80 (1.50-63.83)† 12 (1.58-91.08)†
V-VI 2.80 (0.55-14.23) 0.67 5.56 (1.25-24.77)† 0.67
C = The area under an receiver operating characteristic curve (also known as
c-statistic) provides an overall measure of classification accuracy (representing
the overall proportion of individuals correctly classified), with the value of one
representing perfect accuracy.
* P < 0.001, † P < 0.01
GCS: Glasgow Coma Scale score; GFAP: glial fibrillary acidic protein; GOS:
Glasgow Outcome Scale; OR: odds ratios; UCH-L1: Ubiquitin C-terminal
Hydrolase-L1 protein.
Figure 3 Serum levels of ubiquitin C-terminal hydrolase-L1
protein (UCH-L1) and glial fibrillary acidic protein (GFAP) in
relation to 6 months mortality after severe traumatic brain
injury. Mortality increased with increasing (UCH-L1) and (GFAP)
levels (average serum levels in the first 24 hours).
Figure 4 Spline function analysis showing the association
between the serum ubiquitin C-terminal hydrolase-L1 protein
(UCH-L1) levels and in hospital mortality, probability of
mortality. The risk of mortality increases slowly up to a “threshold”
range of UCH-L1, followed by a more rapid increase and a
subsequent levelling off.
Table 3 Predictive value of serum UCH-L1 and GFAP
levels for death (GOS 1) in hospital after severe
traumatic brain injury
In Hospital Mortality
Variable Cutoff Sensitivity Specificity PPV NPV
UCH-L1 1.89 0.52 0.96 0.52 0.72
GFAP 1.44 0.67 0.86 0.72 0.82
GFAP: glial fibrillary acidic protein; GOS: Glasgow Outcome Scale; NPV:
negative predictive value; PPV: positive predictive value; UCH-L1: ubiquitin C-
terminal hydrolase-L1 protein.
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secondary increases in a specific time (12 to 18 hours)
might also be related to brain surgery.
We also analyzed the relation of UCH-L1 and GFAP
to outcome and compared the accuracy of UCH-L1 and
GFAP for prediction of mortality after TBI.
UCH-L1 was identified as the only independent pre-
dictor of early mortality in a model where GFAP, patient
characteristics (age, sex) and TBI characteristics (CT
findings, GCS) were included as covariates. We believe
that this finding is the consequence of the collinearity
between UCH-L1, GFAP, and the clinical characteristics.
Using a cutoff value of 1.89 ng/ml there was a high spe-
cificity of 96% and a sensitivity of 52% for predicting in-
hospital mortality. The low sensitivity may be explained
by several reasons. In this study, only UCH-L1 levels
within 24 hours post-injury were taken for analysis.
Thus, unfavorable outcomes due to later secondary
brain insults and other complications potentially contri-
buting to poor outcome could not be detected by UCH-
L1. However, the high specificity indicates that initial
serum UCH-L1 may have a potential value as a marker
for major initial brain damage severity.
In agreement with previous studies [21,22], we found
a strong prognostic effect of age on mortality at six
months (OR 1.07, 95% CI 1.03 to 2.11). Interestingly,
although age was the strongest predictor of six months
mortality, it was not related to mortality prior to dis-
charge. A multivariate analysis demonstrated that UCH-
L1 together with age and GCS results in the best predic-
tive model, with a classification accuracy of 94% in dead
versus alive after six months. After age, UCH-L1 was
the strongest predictor of mortality at six months.
Moreover, we found that GFAP with age may also be an
important predictor of outcome at six months after
injury when UCH-L1 was not included in the model.
This result is consistent with previous studies that have
described before the predictive value of GFAP [23]. As
reported by Wardlaw and colleagues [24], we found that
the Marshall CT classification did not remain a signifi-
cant independent outcome predictor on multivariate
analysis when clinical features and (in our study) bio-
markers were included.
UCH-L1 was the only independent predictor of early
mortality and, after age, was the strongest predictor of
mortality at six months. In contrast to the robust pre-
dictive value of UCH-L1, GFAP, and UCH-L1 showed
very different profiles in patients having mass lesions
compared with those having diffuse injuries. However,
these data are consistent with our observation (Figure 5)
and the report of Maas and colleagues [3] that diffuse
brain injury patients (having relatively higher values of
UCH-L1 vs GFAP in our study) had higher mortality
rates at discharge and six months than patients with
mass lesion (Marshall score V to VI).
It is also important to consider why diffuse brain
injury or mass lesions differently affect neurons com-
pared with astroglia. The difference is related to two
important distinctions between neurons and glia. First,
astrocytes are the most numerous cell type in the cen-
tral nervous system, with an astrocyte-to-neuron ratio
that can reach 10:1 in most brain regions [25]. Second,
astrocytes are generally more resistant to ischemia and
other stressors than are neurons and unlike neurons, are
not vulnerable to glutamate excitotoxicity [26]. In dif-
fuse injury, as a consequence of acceleration/decelera-
tion forces, we postulate a predominance of neuronal
cell death resulting in higher levels of UCH-L1 release.
In contrast focal mass lesions are characterized by pan-
necrosis of glial and neuronal elements, and a relative
predominance of glial cell death with higher levels of
GFAP. In addition, a reactive astrogliosis in order to iso-
late the lesion area can occur within a few hours of
brain injury. This evolutionarily conserved function
might also contribute to increased GFAP levels [26].
Our study shows a significant correlation between
serum brain specific protein levels and the hospital
admission GCS. When the correlation of either UCH-L1
and GFAP with the GCS is considered, a positive corre-
lation was found by some authors [6,27] which could
not be confirmed by others [28,29].
UCH-L1 correlated with age in severe TBI patients.
We also examined the correlation among UCH-L1 and
GFAP levels and age in our control group that was not
found statistically significant.
In our study, 41 (51%) of severe TBI patients pre-
sented with a non-evacuated mass lesion (Marshall
score VI) at the first CT. The high rate may be
explained by the time interval between the injury and
the neuroimaging assessment. Indeed 28 of these
Figure 5 Associations between Marshall Score and mortality at
discharge and six months. The percentage mortality was low in
patients with Marshall Score I and II. The highest mortality rate was
observed in patients with Marshall Score III-IV for both in hospital
mortality and at six months.
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patients had a second CT scan within the first 24 hours
showing an evacuated mass lesion (Marshall score V).
This study has several limitations. It would be inter-
esting to compare the prognostic value of UCH-L1 and
GFAP levels and CT findings to measurements of ICP.
As ICP measurements were not available in all of our
patients, we could not perform such an analysis. Other
studies [30,31] have shown that the worst CT scan
obtained during the clinical course has greater predictive
value. However, the intent of our studies was to investi-
gate the prognostic risk of TBI patients on admission.
The predictive analysis examined only in-hospital and
six months mortality. For our study, we chose mortality
rather than the GOS dichotomized into unfavorable ver-
sus favorable since mortality constitutes an objective
endpoint. The high mortality (45.44%) observed in our
study presumably reflects patients having been more
severely injured; a similar rate (49%) was previously
reported in the full International Data Bank.
Conclusions
We report that blood levels of UCH-L1 and GFAP are
an indicator of the severity of brain damage after severe
head trauma and are correlated with prognosis after
trauma. Biomarker profile may be a valuable addition to
traditional approach [32] to the TBI patient. The impor-
tance of a specific biomarker is related to the clinical
question we ask. Moreover, a multimarker strategy
might be also useful in refining risk stratification includ-
ing mortality and morbidity prediction. Finally, different
profile of biomarker release after TBI might provide
useful tools for meaningfully categorizing patients, who
historically have been treated as homogenous groups,
into cohorts based on specific pathobiological processes.
Key messages
• Diffuse injury and focal mass lesion are associated
with different biomarker profiles after severe TBI.
• UCH-L1 and GFAP may be considered both as
efficient diagnostic and severity biomarker of TBI.
• Serum levels of UCH-L1 and GFAP may be a good
prognostic factor for mortality in patients with TBI.
• UCH-L1 and GFAP may provide risk stratifications
of the patients and a characterization of the specific
types of cellular damage mainly involved in primary
injury; potentially leading to a more effectively indi-
vidualized and targeted therapies.
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